Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;23(4):1235-1242.
doi: 10.1007/s10238-022-00927-9. Epub 2022 Nov 13.

Intermediate monocytes expansion and homing markers expression in COVID-19 patients associate with kidney dysfunction

Chiara Dentone #  1 , Daniela Fenoglio #  2   3 , Alessia Parodi #  2 , Tiziana Altosole  3 , Antonio Di Biagio  4   5 , Federica Bozzano  3 , Giorgia Nasi  2 , Antonio Vena  5 , Marina Fabbi  2 , Francesca Ferrera  3 , Bianca Bruzzone  6 , Mauro Giacomini  7 , Daniele Roberto Giacobbe  4   5 , Paolo Pelosi  8   9 , Andrea De Maria  4   5 , Matteo Bassetti  4   5 , Raffaele De Palma  3   10 , Gilberto Filaci  2   3
Affiliations

Intermediate monocytes expansion and homing markers expression in COVID-19 patients associate with kidney dysfunction

Chiara Dentone et al. Clin Exp Med. 2023 Aug.

Abstract

Patients with severe SARS-CoV-2 infection have an overwhelming inflammatory response characterized by remarkable organs monocyte infiltration. We performed an immunophenotypic analysis on circulating monocytes in 19 COVID-19 patients in comparison with 11 naïve HIV-1 patients and 10 healthy subjects. Reduced frequency of classical monocytes and increased frequency of intermediate monocytes characterized COVID-19 patients with respect to both HIV naïve patients and healthy subjects. Intensity of C-C motif chemokine receptor 2 (CCR2) monocyte expression highly correlated with parameters of kidney dysfunction. Our data indicate that highly activated monocytes of COVID-19 patients may be pathogenically associated with the development of renal disease.

Keywords: Covid-19; C–C motif chemokine receptor 2; Innate immunity; Monocytes; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Outside the submitted work: C.D. has received speaker honoraria from Angelini, Novartis, Gilead, ViiV, Shinogi, D. R. G. reports personal consultation fees from Stepstone Pharma GmbH and grants from MSD Italia and Correvio Italia. A.D.B. reports hospital grant from Gilead and consultancy for ViiV, Janssen, MSD, Gilead, Abbvie. M. B. serves on scientific advisory boards for Angelini, AstraZeneca, Bayer, Cubist, Pfizer, Menarini, MSD, Nabriva, Paratek, Roche, Shionogi, Tetraphase, The Medicine Company, and Astellas Pharma Inc, and has received funding for travel or speaker honoraria from Algorithm, Angelini, Astellas Pharma Inc, AstraZeneca, Cubist, Pfizer, MSD, Gilead Sciences, Menarini, Novartis, Ranbaxy, and Teva.

Figures

Fig. 1
Fig. 1
Frequency of circulating monocytes. The frequency of total monocytes out of circulating leucocytes A and those of classical B, intermediate C and nonclassical D monocyte subsets were comparatively analyzed in COVID-19 patients, in HIV + naïve patients and in healthy donors
Fig. 2
Fig. 2
Cytometric features of circulating monocytes. The figure shows the morpho-cytometric characteristics (upper and middle rows) and the relative distribution among the three monocytes subsets (classical, intermediate and nonclassical monocytes) (lower panels) of circulating monocytes on representative samples derived from COVID-19 patient # 8 (middle column), healthy donor #2 (HD, left column) and HIV + naïve patient #1 (right column)
Fig. 3
Fig. 3
Comparison of HLA-DR, CD38 and CCR2 MFI on monocyte subsets derived from healthy donors (HD), COVID-19 and HIV + naïve patients. Box A, Box B and Box C show the comparison of HLA-DR, CD38 and CCR2 MFI (upper row, middle row, lower row, respectively) on classical monocytes (Box A), intermediate monocytes (Box B) and nonclassical monocyte (Box C) derived from healthy donors (HD), COVID-19 patients and HIV + naïve patients, respectively
Fig. 4
Fig. 4
Correlations between CCR2 MFI on circulating monocyte subsets and parameters of renal function in COVID-19 patients. Box A, Box B and Box C show the correlations of serum azotemia (upper row), creatinine (middle row) and GFR (lower row) with CCR2 MFI on classical (Box A), intermediate (Box B) and nonclassical monocytes (Box C), respectively, in COVID-19 patients
See this image and copyright information in PMC

References

    1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19 consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–34. doi: 10.1016/S0140-6736(20)30628-0. - DOI - PMC - PubMed
    1. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–422. doi: 10.1016/S2213-2600(20)30076-X. - DOI - PMC - PubMed
    1. Feng Z, Diao B, Wang R, Wang G, Wang C, Tan Y, Liu L, Wang C, Liu Y, Liu Y, Yuan Z, Ren L, Wu Y. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. medRXiv doi: 10.1101/2020.03.27.20045427.
    1. Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, Tan Y, Wang H, Wang C, Liu L, Liu Y, Liu Y, Wang G, Yuan Z, Hou X, Ren L, Wu Y, Chen Y. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2021;12:2506. doi: 10.1038/s41467-021-22781-1. - DOI - PMC - PubMed
    1. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355–362. doi: 10.1038/s41577-020-0331-4. - DOI - PMC - PubMed

Substances